188973-04-8

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[[(4-amino-5-chloro-2-methoxybenzoyl)amino]methyl]-, 1,1-dimethylethyl ester
• CAS NO: 188973-04-8
• Molecular Formula: C19H28ClN3O4
• Molecular Weight: 397.902
• Mol File: 188973-04-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[[(4-amino-5-chloro-2-methoxybenzoyl)amino]methyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[[(4-amino-5-chloro-2-methoxybenzoyl)amino]methyl]-, 1,1-dimethylethyl ester(188973-04-8)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[[(4-amino-5-chloro-2-methoxybenzoyl)amino]methyl]-, 1,1-dimethylethyl ester(188973-04-8)

Safety Data

• Hazardous Substances Data: 188973-04-8(Hazardous Substances Data)

Upstream product

• 325290-50-4 tert-butyl 4-(azidomethyl)piperidine-1-carboxylate 
• 161975-39-9 tert-butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6457-49-4 4-piperidinemethanol 
• 144222-21-9 4-({[1-Phenyl-meth-(E)-ylidene]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 71207-29-9 N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine 
• 7206-70-4 4-amino-5-chloro-2-methoxybenzoic acid 
• 144222-22-0 tert-butyl 4-(aminomethyl)piperidine-1-carboxylate 

Downstream Products

• 1342815-10-4 N-((1-(3-(1,2,4-triazol-1-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide 
• 1342815-16-0 N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide 
• 1342815-18-2 N-((1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide 
• 220032-26-8 4-amino-5-chloro-2-methoxy-N-((piperidin-4-yl)methyl)benzamide 
• 173340-05-1 4-amino-5-chloro-N-(1-(5-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)-pentyl)piperidin-4-ylmethyl)-2-methoxybenzamide 
• 188971-28-0 4-amino-5-chloro-2-methoxy-N-((1-(5-(2-naphthylmethylamino)pentyl)-piperidin-4-yl)methyl)benzamide 
• 188971-27-9 4-amino-5-chloro-2-methoxy-N-((1-(5-(1-naphthylmethylamino)pentyl)-piperidin-4-yl)methyl)benzamide 
• 188971-25-7 4-amino-5-chloro-N-{1-[5-(cyclohexylmethyl-amino)-pentyl]-piperidin-4-ylmethyl}-2-methoxy-benzamide 
• 173340-04-0 4-amino-5-chloro-N-(1-(4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)butyl)piperidin-4-ylmethyl)-2-methoxybenzamide 
• 188971-21-3 4-amino-5-chloro-2-methoxy-N-((1-(5-(4-methoxybenzylamino)pentyl)piperidin-4-yl)methyl)benzamide 

Relevant articles and documents

Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT4R) Agonist Activities As Potential Agents against Alzheimer's Disease: The Design of Donecopride

In this work, we describe the synthesis and in vitro evaluation of a novel series of multitarget-directed ligands (MTDL) displaying both nanomolar dual-binding site (DBS) acetylcholinesterase inhibitory effects and partial 5-HT4R agonist activity, among which donecopride was selected for further in vivo evaluations in mice. The latter displayed procognitive and antiamnesic effects and enhanced sAPPα release, accounting for a potential symptomatic and disease-modifying therapeutic benefit in the treatment of Alzheimer's disease. (Figure Presented).

A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists

5-HT4 receptor agonists such as tegaserod have demonstrated efficacy in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent disorder characterized by chronic constipation and impairment of intestinal p

MODULATORS OF PERIPHERAL 5-HT RECEPTORS

Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to 5-HT4 receptors, despite the presence of an acidic moiety at the end of an optional chain. The entirely novel entities also exhibit good binding affinity to 5-HT4 receptors. All of the compounds of the invention have a common motif which includes a basic nitrogen moiety and an acidic moiety. The compounds of the invention, due at least in part to their high ionisation potential at physiological pH, have the unique properties of selectively for peripheral 5HT4 receptors over those of the CNS, good binding affinity, and selectively of 5HT4 receptors over other serotonin receptors.